Antifungals: what's in the pipeline

Area of Science:

• Mycology
• Pharmacology
• Infectious Diseases

Background:

• The treatment of fungal infections is evolving with the emergence of drug-resistant strains.
• Traditional antifungal therapies face challenges with efficacy and resistance.
• There is a critical need for novel therapeutic strategies against challenging mycotic pathogens.

Purpose of the Study:

• To review advancements in antifungal drug development.
• To summarize new generation azoles and beta(1,3)-glucan synthesis inhibitors.
• To highlight compounds that have reached late-stage clinical trials.

Main Methods:

• Literature review of recent developments in antifungal agents.
• Analysis of novel azole derivatives and cyclic peptide inhibitors.
• Focus on compounds targeting drug-resistant fungal pathogens.

Main Results:

• New azoles exhibit enhanced bioavailability, half-lives, and safety profiles.
• Acylated cyclic peptides offer a selective mechanism targeting fungal cell-wall synthesis.
• Compounds from both classes are progressing through late-stage clinical development.

Conclusions:

• The development pipeline for antifungal therapies is strengthening.
• Novel azoles and beta(1,3)-glucan inhibitors represent promising therapeutic options.
• Advancements offer hope for managing resistant fungal infections like Candida and Aspergillus.